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Abstract  
Introduction: Myelomatosis is a malignant proliferation of plasma cells in the bone marrow, with relatively high prevalence in African populations. 
Variation in genetic mutations has been observed in individual patients and may be responsible for differences in disease pattern and treatment 
outcomes. This study described the presentations and treatment outcomes of multiple myeloma in nigerian. Methods: The data was obtained 
retrospectively from the case notes of 135 patients diagnosed with multiple myeloma from eight tertiary health institutions across the six 
geopolitical zones of Nigeria from 2005 to 2014. Data analysis was carried out using SPSS 17.0. Results: The predominant presentations were 
bone pain in 97 (74%), nephropathy in 47 (35.9%) and pathological fractures in 58 (44.3%). Sixty-seven percent (67%) of the patients were less 
than 60 years, and 35% had Bence Jones proteinuria. The overall survival beyond 6 months was 91.3%, mean duration of survival rate was 7.4 
months. Majority (66.2%) were on Melphalan alone or on melphalan-containing combinations. A higher packed cell volume (PCV) and total serum 
protein levels at presentation were associated with increased survival, p=0.033 and 0.036, respectively. Conclusion: This study portrayed the 
importance of detail investigation on the causes of bone pain and anaemia in person's aged 40 years and above. There is a high prevalence of 
nephropathy in this cohort of patients which needs to be further investigated. Majority of the patients, though < 65 years of age were placed on 
melphalan-containing combinations, which foreclosed chances of future autologous bone marrow transplantation.  
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Multiple myeloma (MM) refers to the monoclonal proliferation of 
bone marrow plasma cells with attendant bone disease and clinical 
features associated with marrow invasion. There is marked 
variability in the clinical features seen in this patient population, 
from the apparently healthy patients to the debilitated ones with 
anaemia and pathological fractures, with or without nephropathy 
[1].  
  
The Haematological Malignancy Research Network (HMRN) [2] 
region for 2004-2009 described lower rates of myeloma incidence in 
the more deprived areas for both sexes combined while the 
England-wide data for 2000-2004 earlier documented a similar rate 
only in females [3]. These observations are compatible with the 
theory that socio-economic factors impact on the likelihood of 
recognizing the non-specific symptoms common in myeloma which 
inform the attitude to seeking medical care [4,5].  
  
Previous data from the Statistics, Epidemiology and End Result 
(SEER) program showed a significantly better survival in blacks with 
MM, compared with whites [6,7]. Though monoclonal, several 
mutations have been associated with the malignant transformation 
as well as prognosis of this disease, a recent study has shown 
variations in the prevalence of t(11;14), t(4;14), monosomy 
13/del13q and monosomy 17/del17p, with blacks having lower 
figures [8].Clinical features as well as outcomes of treatment are 
known to vary according to the underlying genetic mutations and 
thus confer unique disease features. Chemotherapeutic options in 
diagnosed cases of MM involve patient stratification based on age, 
presence of co-morbidities and peculiar mutations detected in each 
patient [9]. In the African setting, challenges in the aspect of 
patients? investigative assessment as well as affordability and 
access to first line medications and transplant facilities are quite 
limited. This invariably affects treatment outcomes and survival. 
Previous single centre study conducted by Madu et al in 
southeastern Nigeria placed duration of follow up at 24 weeks [10].  
  
This is a multi-centre retrospective study aimed at providing a 
broader assessment of clinical and biomedical features of patients 
with MM in Nigeria. Therapeutic choices and treatment outcomes 
among this patient population were also analysed for evidence-





The data was obtained retrospectively from the case notes of 135 
patients diagnosed with multiple myeloma from eight tertiary health 
institutions across the six geopolitical zones of Nigeria from 2005 to 
2014. The information obtained included; clinical and laboratory 
features at presentation, chemotherapeutic regimen used, mortality 
and duration from diagnosis to death or last appointment. Each 
centre obtained ethical approval from their institution in addition to 
the approval obtained from the Nigerian Institute of Medical 
research Institute Review Board (IRB).  
  
Data analysis was carried out using SPSS 17.0 (IL, Chicago), and 
Spearmann as well as Kendaulltau_b to assess relationship between 
nominal and ordinal data. Kaplan -Meier survival was estimated and 
the curve was plotted using the same software. Values were 





Of the 135 patients studied, 70(58.9%) were males and 65 (48.1%) 
were females. The median age of the patients was 60 years and a 
mean 58.8 ± 11.2 years. Bone pain was the presenting feature in 
97 (74%) of the patients, while 58 (44.3%) of the patients had 
pathological fracture at presentation and 47 (35.9%) had 
nephropathy. Table 1 shows the distribution of the patients among 
the participating centres. Hypertension was observed as a 
predominant co-morbidity in 60% (15/25) of patients.  
  
Majority (77%) of the patients were moderate to severe anaemia at 
presentation with a median haemoglobin concentration of 8.3g/dL, 
and a mean value of 8.4 ± 2.1g/dL. The median values of the total 
protein, albumin and globulin were found to be 7.6, 3.4 and 4.7g/L, 
respectively. Bone marrow plasmacytosis was observed in all 
patients with a median percentage of 28.5%, and serum calcium 
had a median value of 2.7mmol/L, and a mean value of 5.0 ± 5.5 
mmol/L. Of the 68 patients assessed for Bence Jones proteinuria, 24 
(35.3%) were positive while 44 (64.7%) were negative. Serum 
protein electrophoresis showed a monoclonal gamma band in 38 
(45%) of the patients, but absent in 66 (55%) of cases.  
  
There was a significant relationship between the occurrence of 
pathological fractures and a lower serum calcium level with a 
correlation coefficient of 0.267 (p=0.004).There was also a 
significant relationship between increasing age and the presence of 
Bence Jones proteinuria (BJP) and nephropathy (correlation 
coefficient of 0.229 (p=0.039) and 0.144 (p=0.046)) 
respectively.The serum globulin level is also associated with the 
presence of BJP and percentage of bone marrow plasmacytosis; 
0.252 (p=0.012) and 0.368 (p=0.001), respectively. Patients who 
had a higher PCV at presentation seemed to have a higher 
probability of not excreting BJP in urine as shown in Figure 1. A 
higher total serum protein value was also associated with increased 
survival coefficient of 0.190 (p=0.036). Patients with a higher PCV 
at presentation were also noted to survive longer, coefficient of 
0.202 (p=0.033) and as shown in Figure 2.  
  
Pathological fractures as depicted in Figure 3 do not seem to occur 
more in the older patients, nor do they seem to be more prevalent 
in any particular gender.However the prevalence of pathological 
fractures seems to be fairly well distributed across the various ages 
irrespective of their serum globulin levels (Figure 4). Males seem to 
survive longer than females (Figure 5).  
  
A great number (48.6%) of the patients received melphalan-based 
combinations (melphalan/prednisolone (MP) 30.6% and 
melphalan/prednisolone/ thalidomide (MPT) 18.4%). Only 5 
(13.9%) patients aged less than 65 years received the first line drug 





The demographic variables in this study were found to be similar to 
those obtained in other studies on multiple myeloma patients in 
Nigeria by Madu et al [10] and Fasola et al [1]; majority being 
females with median age of 60 years. Bone pain seemed to 
predominate as a presenting feature and in most cases associated 
with anaemia. Hence the occurrence of these features in a patient 
aged 40 years and above should raise a high index of suspicion for 
multiple myeloma. Our results also indicated that though Bence 
Jones proteinuria (BJP) was seen in some patients, a significant 
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number of patients were negative for Bence Jones proteinuria. This 
may be a possible outcome of the variations in the genetic 
mutations responsible for initiating this malignancy, which has been 
observed across the different races as recently reported by 
Greenberg et al [11]. The reliance on the BJP and serum protein 
electrophoresis as a diagnostic protocol, may lead to several missed 
cases, as the results of this study have shown their low specificity.  
  
Pathological fracture is a major cause of increased morbidity in 
patients with multiple myeloma and could predispose to paraplegia 
with adverse effects on survival [12]. This complication was present 
in 58 (44.3%) of cases in this study and did not correlate with age 
of patients (Figure 3). Even though fractures increase with age in 
the general population [13], this may not be the case in patients 
with multiple myeloma as fractures may be an indication of bone 
disease and not necessarily bone ageing.  
  
Hypercalcaemia is a frequent metabolic complication in patients with 
multiple myeloma; occurring in up to 1/3 of cases[14]. It is closely 
linked with the development of myeloma bone disease, particularly 
pathological fractures, and stems from loss of bone density due to 
osteolysis, with efflux of calcium into the extracellular fluid. Bone 
resorption in patients with multiple myeloma is thought to be 
mediated by a number of cytokines, including receptor activator of 
nuclear factor kappa -B ligand (RANKL), macrophage inflammatory 
protein (MIP) 1α and tumour necrosis factors (TNFs) which are 
either secreted by the myeloma cells or by other accessory cells 
involved in cell-cell interactions within the marrow micro-
environment [15]. In spite of the reported high frequency of 
hypercalcaemia and its association with myeloma bone disease, this 
study observed that lower serum calcium levels were positively 
associated with occurrence of pathological fractures. While this may 
appear contradictory, other reports have noted that hypercalcaemia 
may not be consistently associated with myeloma bone disease and 
may even be a late (terminal) feature of multiple meloma [14, 16]. 
These reports showed that hypercalcaemia was not present in all 
myeloma patients that had significant bone disease and surmised 
that the relationship between hypercalcaemia and myeloma bone 
disease may not be limited to osteoclastic activation (with increased 
bone resorption) but could involve other influences such as those 
related to myeloma cell mass, glomerular filtration status and 
disease duration. It may thus appear that these (other) influences 
predominate in our patients and could account for the positive 
relationship observed between low serum calcium and the 
occurrence of pathological fractures in this study.  
  
A little less than half of the patients had already developed 
nephropathy at the point of diagnosis. Similar prevalence of this 
complication had been reported by previous authors. The study at 
Ibadan by Fasola et al reported that about one-third of the patients 
had renal failure while a further two-thirds had renal insufficiency 
[1]. It should be further investigated if this was a consequence of 
late presentation or a peculiar feature of MM in Nigeria. Other 
factors such as presence of co-morbidities (especially hypertension) 
should be ruled out as contributing to the increase in prevalence of 
renal dysfunction. Also other known causes of nephropathy in MM 
such as amyloidosis, hypercalcaemia, anaemia and recurrent urinary 
tract infections should be vigorously investigated in all suspected 
cases. According to the study by Fasola et al [1], hypercalcaemia 
was a common feature of patients who had developed renal failure 
compared with those that had normal renal function.  
  
The presence of Bence Jones protein in urine at presentation seems 
to have some interesting associations with; age, serum globin level 
and percentage of marrow plasmacytosis. These findings can be 
explained to a large extent from the fact that the protein is 
produced by the malignant plasma cells and occupies the globin 
fraction of the plasma proteins. Sinohara et al reported that 
approximately 50% of BJP are catabolized in the kidneys [17]. 
Therefore, its occurrence with increasing age seems to infer that the 
renal reabsorption capacity of the protein diminishes with age and 
therefore Bence Jones proteinuria should be expected in the older 
patients with MM.  
  
A higher serum protein level as well as PCV was associated with 
improved survival. These parameters are usually used in assessing 
degree of well-being in chronically ill patients. These patients are 
therefore more likely to tolerate chemotherapy and withstand 
infections better. Whether this can be translated to mean that 
optimizing the PCV and serum proteins always in MM patients would 
markedly improve survival, has to be further evaluated. This may 
also imply that dietary considerations may play a major role in the 
management of patients in this setting, as had been suggested in 
previous publications [6,18]. It remains to be evaluated whether 
increasing the protein (albumin) content of diet or optimizing the 
haemoglobin concentration as part of the management protocol, in 
MM will improve survival.  
  
Majority of the patients across the various participating centres 
received melphalan either alone or in combination with other 
cytotoxic drugs, irrespective of age or eligibility for bone marrow 
transplants (BMT). This falls short of the current best practice with 
regard to management of MM. Financial constraints and lack of 
availability of first choice drugs for use in younger patients has 
limited the treatment options available to haem-oncologists in 
Nigeria. The increased survival and relapse rate obtained with the 
newer drugs may need to be replicated in this patient population as 
satisfactory results have been obtained with alternative 
combinations. This further underlines the need to characterize the 
predominant cytogenetic mutations in this cohort in order to 





The importance of having a high index of suspicion of MM in 
patients aged 40 years and above presenting with bone pain and 
anaemia cannot be over-emphasized. The predictive factors for the 
causation of nephropathy in MM need to be further evaluated to 
help prevent this predominant complication which negatively affects 
survival. A higher haemoglobin concentration and serum protein 
positively affect survival and this should be exploited in aspects of 
management. Most of the patients were placed on melphalan-
containing combinations, irrespective of their age. Newer, first line 
drugs should not only be made available, but also tried in this 
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Figure 2: Relationship between haemoglobin concentration at diagnosis and 
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Figure 3: Occurrence of pathological fractures in 




Figure 4: Age and serum globulin distribution in 




Figure 5: Kaplan Meier survival curve in males and 
females with myeloma 
 
 
